Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.49 |
| ▸ | UTS2R | Q9UKP6 | 6/20 | 0.48 |
| ▸ | UBE2N | P61088 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 2/20 | 0.42 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4522709 | 1.00 | CCR1 (0.49) | CCR1UTS2RUBE2NCHRM1NPC1 | |
| SCHEMBL6890168 | 0.84 | BACE1 (0.50) | BCHEBACE1SLC6A11 | |
| SCHEMBL6890165 | 0.84 | BACE1 (0.50) | BCHEBACE1SLC6A11 | |
| SCHEMBL26834640 | 0.84 | HDAC3 (0.49) | NPC1RAB9ABCHEBACE1SLC6A11 | |
| SCHEMBL9012913 | 0.81 | BACE1 (0.50) | NPC1RAB9ABCHEBACE1SLC6A11 | |
| SCHEMBL4523139 | 0.81 | CNR2 (0.51) | NPC1RAB9A | |
| SCHEMBL4522530 | 0.81 | CNR2 (0.51) | NPC1RAB9A | |
| SCHEMBL22626791 | 0.80 | TRPA1 (0.54) | NPC1RAB9ABCHEBACE1SLC6A11 | |
| SCHEMBL24414242 | 0.79 | MMP9 (0.48) | NPC1RAB9A | |
| SCHEMBL10707926 | 0.77 | BACE1 (0.47) | NPC1RAB9ABCHEBACE1SLC6A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1697308-B1 | PHENYLAMIDE AND PYRIDYLAMIDE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (US) | 2014-03-19 | — | — | EP | disclosed |
| US-7550481-B2 | Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of Alzheimer's disease | MERCK & CO., INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-20070142634-A1 | Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease | MERCK SHARP & DOHME LLC | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142634-A1 | Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease | BACE1, BACE2, APP | CCR1 4825/4885UTS2R 3108/4885UBE2N 1253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.